Kymera Therapeutics

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

Company to begin hosting quarterly calls to provide broad updates across pipeline WATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein